The Australasian Severe Asthma Registry (ASAR) is a multi-national clinical quality registry of individuals with confirmed severe refractory asthma and non-severe controlled asthma.
ASAR (previously SAWD) was established by the Australasian Severe Asthma Network (ASAN) in 2013. It is the under the management of the ASAN Steering Committee and governance of the Thoracic Society of Australia and New Zealand (TSANZ).
There are 22 Australasian Severe Asthma Registry (ASAR) centres, located in Australia and New Zealand. Appropriate human research ethics committee/institutional review board and local research governance approvals are in place for the conduct of the registry.
The main purposes of ASAR are:
ASAR also serves as a Databank for future approved research studies. ASAR is flexible and enables the implementation of new research modules.
Patients with diagnosed severe refractory asthma and non-severe controlled asthma are systematically assessed at registration and followed up prospectively for up to 10-years. The data is submitted to a secure online database. The information collected includes non-identifying demographic details, clinical data and patient-reported outcomes.
Laura Mitchell
A/ GPO Box 1491 Sydney, NSW 2001
P/ 02 9222 6200 W/ thoracic.org.au
ASAR is supported by AstraZeneca, GlaxoSmithKline, Novartis and Sanofi.
Last Updated on
